OQS
TSHA icon

Occudo Quantitative Strategies’s Taysha Gene Therapies TSHA Stock Holding History

Occudo Quantitative Strategies’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,679
Closed -$28K – 1381
2022
Q3 		$28K Sell
14,679
-16,351
-53% -$59.4K ﹤0.01% 1122
2022
Q2 		$115K Buy
31,030
+4,702
+18% +$18.7K 0.01% 1005
2022
Q1 		$172K Buy
+26,328
New +$197K 0.01% 968

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Occudo Quantitative Strategies's TSHA Position: Q4 2022 in Review

Occudo Quantitative Strategies sold out of Taysha Gene Therapies (TSHA) in Q4 2022, closing a stake of 14,679 shares — an estimated $28K sold.

Occudo Quantitative Strategies first reported a position in TSHA in Q1 2022 and held it in 3 quarters. The position peaked at $172K in Q1 2022. 52 funds tracked by Wall St. Rank hold TSHA as of Q4 2022.

  • Occudo Quantitative Strategies reported no remaining Taysha Gene Therapies position as of Q4 2022 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 14,679 Taysha Gene Therapies shares in Q4 2022, an estimated $28K.
  • Occudo Quantitative Strategies first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Taysha Gene Therapies position peaked at $172K in Q1 2022.
  • 52 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.